{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:59:33Z","timestamp":1775476773948,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40744-025-00789-z","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:46:26Z","timestamp":1755247586000},"page":"1007-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of Super-Responder Profile in Patients with Psoriatic Arthritis Treated with b\/tsDMARDs: A Retrospective Study of a Longitudinal Cohort"],"prefix":"10.1007","volume":"12","author":[{"given":"Fabio Massimo","family":"Perrotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3899\/jrheum.190054","volume":"46","author":"E Lubrano","year":"2019","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46:1428\u201330.","journal-title":"J Rheumatol"},{"key":"789_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"789_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3899\/jrheum.170112","volume":"44","author":"E Lubrano","year":"2017","unstructured":"Lubrano E, De Socio A, Perrotta FM. Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort. J Rheumatol. 2017;44(8):1159\u201364. https:\/\/doi.org\/10.3899\/jrheum.170112.","journal-title":"J Rheumatol"},{"issue":"1","key":"789_CR4","doi-asserted-by":"publisher","first-page":"e001519","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7(1):e001519.","journal-title":"RMD Open"},{"issue":"2","key":"789_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3899\/jrheum.150805","volume":"43","author":"FM Perrotta","year":"2016","unstructured":"Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-\u03b1 drugs. J Rheumatol. 2016;43(2):350\u20135.","journal-title":"J Rheumatol"},{"issue":"17","key":"789_CR6","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.3390\/jcm13175175","volume":"13","author":"L Marcelli","year":"2024","unstructured":"Marcelli L, Belcastro A, Talamonti M, et al. Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: a long-term real-life experience. J Clin Med. 2024;13(17):5175.","journal-title":"J Clin Med"},{"issue":"1","key":"789_CR7","doi-asserted-by":"publisher","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","volume":"35","author":"Y Liu","year":"2024","unstructured":"Liu Y, Hu K, Jian L, Duan Y, Zhang M, Kuang Y. Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year. J Dermatolog Treat. 2024;35(1):2331782.","journal-title":"J Dermatolog Treat"},{"key":"789_CR8","doi-asserted-by":"publisher","unstructured":"Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life Basel. 2022;12(9):1412. https:\/\/doi.org\/10.3390\/life12091412.","DOI":"10.3390\/life12091412"},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"789_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3899\/jrheum.190679","volume":"47","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Residual disease activity and associated factors in psoriatic arthritis. J Rheumatol. 2020;47(10):1490\u20135.","journal-title":"J Rheumatol"},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391.","journal-title":"Arthritis Rheum"},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3899\/jrheum.150595","volume":"42","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A. Patient\u2019s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332\u20138.","journal-title":"J Rheumatol"},{"key":"789_CR14","doi-asserted-by":"crossref","unstructured":"Cauli A, Gladman DD, Mathieu, GRAPPA 3PPsA Study Group, et al. Physician\u2019s Global Assessment in Psoriatic Arthritis: a multicenter GRAPPA study. J Rheumatol. 2018;45(9):1256\u201362.","DOI":"10.3899\/jrheum.171183"},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"789_CR16","doi-asserted-by":"publisher","first-page":"e001170","DOI":"10.1136\/rmdopen-2020-001170","volume":"6","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Ca\u00f1ete JD, Perrotta FM. Assessment of the patient acceptable symptom state (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6:e001170.","journal-title":"RMD Open"},{"key":"789_CR17","unstructured":"Ranza R, Marchesoni A, Calori G, et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol. 1993;11:123\u20138."},{"key":"789_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3899\/jrheum.150826","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43:371\u20135.","journal-title":"J Rheumatol"},{"issue":"1","key":"789_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3899\/jrheum.180267","volume":"46","author":"LC Coates","year":"2019","unstructured":"Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS. What should be the primary target of \"treat to target\" in psoriatic arthritis? J Rheumatol. 2019;46(1):38\u201342.","journal-title":"J Rheumatol"},{"issue":"12","key":"789_CR20","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1007\/s10067-024-07193-y","volume":"43","author":"T K\u00fcnzler","year":"2024","unstructured":"K\u00fcnzler T, Bamert M, Sprott H. Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis. Clin Rheumatol. 2024;43(12):3723\u201346.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"789_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-023-01072-1","volume":"14","author":"E Errichetti","year":"2024","unstructured":"Errichetti E, Zabotti A. Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors. Dermatol Ther (Heidelb). 2024;14(1):1\u20133.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"789_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/1744666X.2021.1825941","volume":"16","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis - a perspective. Expert Rev Clin Immunol. 2020;16:963\u201372.","journal-title":"Expert Rev Clin Immunol"},{"key":"789_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123\u201331.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00789-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00789-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00789-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T10:28:38Z","timestamp":1758364118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00789-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00789-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ennio Lubrano and Fabio Massimo Perrotta are members of the Editorial Board of Rheumatology and Therapy. Ennio Lubrano and Fabio Massimo Perrotta were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the institutional review board of the University of Molise (protocol no. 0001-017-2021) and performed according to the Helsinki declaration. Written informed consent to use clinical data of all participants was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}